BenevolentAl Therapeutics Pipeline and Triage
250
200
150
aSyn area/TH neurons
(% of control, TH)
100
50
Control
MPP+ 4UM/48h
100-
80-
TH number (% of control)
60-
40-
20-
Abl inhibitor is neuroprotective in in vitro Parkinson's
MMP+ induced TH neuron toxicity and
a-synuclein aggregation in mouse primary
dopaminergic neuron cultures'
120
disease and ALS models
Tunicamycin induced apoptosis of sporadic ALS
patient iPSC derived motor neurons²
8.0x 105-
Glutamate induced apoptosis of sporadic ALS
patient iPSC derived motor neurons²
8.0x 10-
Control
Control
MPP+ 4μM/48h
(10 nM)
(30 nM)
(100 nM)'
(300 nM)
(1 μM)
(3 µM)
(10 µM)
Ben-B
(10 nM)
(30 nM)
(100 nM)
(300 nM)
(1 μM)
(3 μM)
(10 μM)
+ BDNF (50 ng/mL)
+ BDNF (50 ng/mL)
Total Red Object Area
(μm²/Well)
6.0x 105-
4.0x 105-
2.0x 105-
8.0x 105-
6.0x105-
0
T
Total Red Object Area
(μm²/Well)
4.0x 105-
2.0x105-
Ben-B
'Data from Neurosys. 2Data from iXcell (both CROS are engaged by the Company to provide services for this programme)
No Stim Ctrl
Tunicamycin
10 μM
50
100
150
200
250
Time (h)
***
**
Ben-B
1 μM
0.1 M
0.01 μM
No Stim Ctrl
Tunicamycin
-10 μM
1 μM
-0.1 μM
-0.01 μM
Total Red Object Area
(μm²/Well)
6.0x 105-
4.0x 105-
2.0x 10-
8.0×105-
6.0x105-
Total Red Object Area
(μm²/Well)
4.0×105-
2.0x105-
0+
0
50
100
150
200
250
Time (h)
No Stim Ctrl
Glutamate
10 μM
***
***
****
T
1 μM >
0.1μM
0.01μM
Ben-B
Benevolent 49
Glutamate
10 μM
1 μM
0.1μM
0.01 μMView entire presentation